Constitutive activation of NF-κB inducing kinase (NIK) in the mesenchymal lineage using Osterix (Sp7)- or Fibroblast-specific protein 1 (S100a4)-Cre drives spontaneous soft tissue sarcoma by Davis, Jennifer L et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
1-1-2021 
Constitutive activation of NF-κB inducing kinase (NIK) in the 
mesenchymal lineage using Osterix (Sp7)- or Fibroblast-specific 
protein 1 (S100a4)-Cre drives spontaneous soft tissue sarcoma 




Heather M. Zannit 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Jennifer L. Davis, Roman Thaler, Linda Cox, Biancamaria Ricci, Heather M. Zannit, Fei Wan, Roberta 
Faccio, Amel Dudakovic, Andre J. van Wijnen, and Deborah J. Veis 
RESEARCH ARTICLE
Constitutive activation of NF-κB inducing
kinase (NIK) in the mesenchymal lineage using
Osterix (Sp7)- or Fibroblast-specific protein 1
(S100a4)-Cre drives spontaneous soft tissue
sarcoma
Jennifer L. DavisID
1,2, Roman Thaler3,4, Linda Cox1,2, Biancamaria RicciID
1,5, Heather
M. Zannit1,5, Fei Wan6, Roberta Faccio1,5,7, Amel Dudakovic3,4, Andre J. van Wijnen3,4,
Deborah J. VeisID
1,2,7*
1 Musculoskeletal Research Center, Washington University School of Medicine, St. Louis, MO, United States
of America, 2 Department of Medicine, Division of Bone and Mineral Diseases, Washington University School
of Medicine, St. Louis, MO, United States of America, 3 Department of Orthopedic Surgery, Mayo Clinic,
Rochester, MN, United States of America, 4 Department of Biochemistry and Molecular Biology, Mayo Clinic,
Rochester, MN, United States of America, 5 Department of Orthopaedic Surgery, Washington University
School of Medicine, St Louis, MO, United States of America, 6 Department of Surgery, Division of Public
Health Sciences, Washington University School of Medicine, St. Louis, MO, United States of America,
7 Shriners Hospitals for Children–St. Louis, St. Louis, MO, United States of America
* dveis@wustl.edu
Abstract
Aberrant NF-κB signaling fuels tumor growth in multiple human cancer types including both
hematologic and solid malignancies. Chronic elevated alternative NF-κB signaling can be
modeled in transgenic mice upon activation of a conditional NF-κB-inducing kinase (NIK)
allele lacking the regulatory TRAF3 binding domain (NT3). Here, we report that expression
of NT3 in the mesenchymal lineage with Osterix (Osx/Sp7)-Cre or Fibroblast-Specific Pro-
tein 1 (FSP1)-Cre caused subcutaneous, soft tissue tumors. These tumors displayed signifi-
cantly shorter latency and a greater multiple incidence rate in Fsp1-Cre;NT3 compared to
Osx-Cre;NT3 mice, regardless of sex. Histological assessment revealed poorly differenti-
ated solid tumors with some spindled patterns, as well as robust RelB immunostaining, con-
firming activation of alternative NF-κB. Even though NT3 expression also occurs in the
osteolineage in Osx-Cre;NT3 mice, we observed no bony lesions. The staining profiles and
pattern of Cre expression in the two lines pointed to a mesenchymal tumor origin. Immuno-
histochemistry revealed that these tumors stain strongly for alpha-smooth muscle actin
(αSMA), although vimentin staining was uniform only in Osx-Cre;NT3 tumors. Negative
CD45 and S100 immunostains precluded hematopoietic and melanocytic origins, respec-
tively, while positive staining for cytokeratin 19 (CK19), typically associated with epithelia,
was found in subpopulations of both tumors. Principal component, differential expression,
and gene ontology analyses revealed that NT3 tumors are distinct from normal mesenchy-
mal tissues and are enriched for NF-κB related biological processes. We conclude that
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constitutive activation of the alternative NF-κB pathway in the mesenchymal lineage drives
spontaneous sarcoma and provides a novel mouse model for NF-κB related sarcomas.
Introduction
NF-κB signaling is best known for its pivotal roles in innate and adaptive immunity [1]. How-
ever, this transcription factor family can also regulate both physiologic and pathologic pro-
cesses outside of the immune system such as in bone and skin, and has been implicated in
tumorigenesis [1–4]. The NF-κB pathway has two principal arms, classical and alternative.
Under basal conditions, the five NF-κB subunits (RelA/p65, c-Rel, RelB, p50, and p52), which
dimerize to form transcription factors, remain in the cytoplasm bound to inhibitors of κB
(IκBs) rendering them inactive. A multitude of stimuli (including inflammation, pathogens,
and DNA damage) can trigger a rapid classical NF-κB cascade which usually resolves in min-
utes to hours. Classical signaling is largely mediated through TAK1 phosphorylation of the
IKKα/β/γ complex resulting in release of p65-containing dimers [5]. On the other hand, a
much more limited repertoire of inputs feeds into the alternative NF-κB pathway (BAFFR,
LtβR, CD40, RANKL). Induction of alternative NF-κB signaling requires de novo transcrip-
tion and results in much slower kinetics on the order of hours to days. The alternative NF-κB
pathway is triggered exclusively through NF-κB-inducing kinase (NIK) which phosphorylates
IKKα to mobilize RelB/p52-containing dimers into the nucleus [1, 6]. Both RelB and Nfkb2,
the gene encoding p52, have κB binding sites in their promoters and are transcriptionally
upregulated by classical NF-κB stimuli. Importantly, overexpression and/or activating muta-
tions in NIK can drive both classical and alternative signaling arms. Thus, while activation of
either the classical or the alternative NF-κB program is highly stimulus-dependent, significant
crosstalk exists between these two pathways [7].
Although direct mutations in upstream kinases or DNA-binding subunits of the NF-κB
pathway are relatively rare, hyperactivation of NF-κB signaling is a common feature of a vari-
ety of cancers [8, 9]. Perturbations of the NF-κB pathway are prevalent in hematological malig-
nancies, particularly B-cell lymphomas and multiple myeloma, but also drive many solid
tumors (breast, liver, lung, prostate, and others) [10]. Moreover, elevated NF-κB expression is
associated with worse overall survival in solid tumors [11]. NF-κB interacts with other signal-
ing pathways such as mTOR, and with both transcriptional coactivators (CBP) as well as tran-
scriptional corepressors (SMRT) to spur tumor growth [12]. NF-κB is also well-documented
to antagonize the classical tumor suppressor p53 pathway in multiple cancer types [3]. Less
commonly, NF-κB signaling is tumor suppressive as reflected by tumor formation in mice
exhibiting loss of IKKγ in liver [13] and IKKα in skin [14]. Thus, dysregulation of NF-κB, in
either direction, may promote tumor proliferation.
Compared to classical NF-κB, far less studies have been published on the alternative path-
way, even though the pinnacle kinase of this signaling arm, NIK, is activated in multiple cancer
types, including multiple myeloma, carcinomas (pancreas, ovarian and lung) and melanoma
[15, 16]. Downstream of NIK, increased expression of the alternative NF-κB subunits RelB
and/or p52 has been implicated in the pathogenesis of various other carcinomas and gliomas
[17, 18]. Additionally, transcriptional activity of RelB/p52 can cooperate with genome stability
enzymes, such as APOBECs and the TERT catalytic subunit of telomerase, to fuel tumor
growth [19, 20]. Lastly, RelB/p52 can regulate the transcriptional suppressor EZH2 which
inhibits transcription of well-known tumor suppressors (p16Ink4a and p14ARF) and p53 target
genes [17] in a variety of cancer types.
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Alternative NF-κB pathway output is tightly controlled with multiple layers of negative
feedback, all coalescing to maintain low basal NIK levels [6]. Normally, NIK is bound to
TRAF2/3 and is continually K48-ubiquitinated by the E3 ligase, cIAP1/2, tagging it for protea-
somal degradation. Upon signal induction, cIAP1/2 instead ubiquitinates TRAF3, leading to
stabilization and accumulation of NIK. Removal of the TRAF3 binding domain of NIK stabi-
lizes protein levels, leading to persistent elevation of alternative NF-κB signaling. Transgenic
mice bearing a NIK allele lacking the TRAF3 binding motif (NT3) downstream of a loxP/Neo-
STOP/loxP cassette knocked into the ROSA26 locus permit targeted expression of a constitu-
tively active form of NIK with any Cre-recombinase driver [21]. Given the critical function of
NIK in multiple myeloma [15], it was quite surprising that NT3 mice crossed to CD19-Cre
(pre B-cell) presented only with B-cell hyperplasia and not lymphoma or myeloma [21]. How-
ever, other studies using CD19-Cre show that insults to either Bcl6 [22] or Notch [23], in con-
junction with the NT3 transgene, did lead to oncogenic transformation. The NT3 allele
expressed in T-cells caused fatal inflammation and autoimmunity, but not lymphoma [24].
NT3 expression early in the hematopoietic lineage also drove unchecked inflammation as well
as bone marrow failure, but again, the pathogenesis in these mice arrested as a myeloid dys-
plastic syndrome rather than frank malignancy. Surprisingly, inducible global expression of
NT3 delayed the onset of acute myeloid leukemia driven by another oncogene [25]. In sum,
NT3 allele expression in these studies is necessary but not sufficient to promote tumor growth
and may in some instances even suppress tumor formation.
Our laboratory has recently shown that constitutive activation of NIK in the osteolineage in
Osterix-Cre;NT3 (Osx-Cre;NT3) mice enhances both basal and loading-induced bone forma-
tion [26]. Unexpectedly, these Osx-Cre;NT3 mice also developed malignant subcutaneous, soft
tissue tumors in early adulthood. To date, there have been very limited reports of either classi-
cal or alternative NF-κB involvement in sarcomas. Balkhi and colleagues found increased NF-
κB activity across a panel of human sarcoma cell lines [27]. In another study, targeted sequenc-
ing of human follicular dendritic cell sarcomas revealed a loss of the NF-κB regulatory genes
(NFKBIA, CYLD, and A20) in ~38% of samples [28]. While NIK has been shown to directly
interact with the transmembrane K15 protein in viral-associated Kaposi sarcoma, downstream
signaling output converged on the classical subunit p65 [29]. Finally, a hybrid approach utiliz-
ing both human and murine models of undifferentiated pleomorphic sarcoma found NF-κB
to be the most transcriptionally active pathway in these tumors, through crosstalk with YAP1
signaling. Moreover, inhibition of p65 was shown to reduce tumor burden [29]. Importantly,
the aforementioned studies linking NF-κB and sarcoma mainly focused on the role of the clas-
sical NF-κB pathway in promoting oncogenesis.
Here, we report that conditional activation of NIK in Osx-Cre;NT3 mice, as well as in mice
with alternative NF-κB expression broadly in the mesenchymal lineage, using Fibroblast-spe-
cific protein 1-Cre (FSP1-Cre;NT3), promotes tumorigenesis. Histology, immunohistochemis-
try and RNA-Seq analyses confirmed mesenchymal derivation. To our knowledge, this is the
first report of an alternative NF-κB activation driver in sarcoma.
Materials and methods
Mice
Mice were housed communally in a temperature-controlled, pathogen-free barrier facility,
with 12-hour light/dark cycles, and had ad libitum access to fresh chow and water. Mice were
observed daily by Division of Comparative Medicine (DCM) staff and 1–2 times a week by lab-
oratory personnel. Tumor-bearing animals were euthanized at a humane endpoint before
tumor size surpassed ethical limits (2cm). Any other health concerns were reported promptly
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to the DCM veterinarian and all treatment or euthanasia recommendations followed. All pro-
tocols were approved by Institutional Animal Studies Committee at Washington University
School of Medicine (ASC protocol #19–1059). Details addressing Animal Research: Reporting
of In Vivo Experiments (ARRIVE) guidelines for study design, sample size, outcome measures,
statistical methods, experimental animals, experimental procedures, and results are indicated
in their respective sections. No animals were excluded from analyses. As only Cre-positive ani-
mals developed tumors, randomization and blinding by genotype was not possible in our
studies.
The transgenic mouse lines NIKΔT3 (NT3) [21] on a C57Bl/6J background and Osx1-GFP::
Cre Tet-OFF (Osx-Cre) [30] on a mixed C57Bl/6J and CD1 background were as previously
described. FSP1-Cre (S100a4-Cre) [31] mice on a FVB/n background were a gift from Dr.
Gregory Longmore [32]. Osx-Cre;TdT mice were generated by crossing the following lines
from The Jackson Laboratory, USA: B6.Cg-Tg(Sp7-tTA,tetO-EGFP/Cre)1Amc/J (catalog
#006361) and B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J (TdT) (catalog #007909) [33]. All
parental lines were maintained separately due to strain differences. Homozygous NT3 females
were crossed to heterozygous Osx-Cre males to generate Osx-Cre;NT3 mice or to heterozygous
FSP1-Cre males to generate FSP1-Cre;NT3 mice. Control (Ctrl) animals are the Cre-negative
littermates from each crossing. Genotyping was performed on tail DNA using a REDExtract-
N-Amp Tissue PCR kit (XNAT, Millipore Sigma, USA). Primer sequences and run conditions
are listed in S1 Table. Osx-Cre;NT3 or Osx-Cre;TdT and their Ctrl littermates were fed a
200ppm doxycycline chow (Purina Test Diet #1816332–203, St. Louis, MO, USA) until wean-
ing (P21-P22) then switched to standard chow to induce NT3 or Tdt transgene expression
(Purina 5058, St. Louis, MO, USA).
Tumor latency and multiple tumor incidence
Mice were checked 1–2 times weekly for the presence of at least one palpable tumor mass and
both the age and number of tumor masses per animal at this time was recorded. Multiple
tumor incidence was defined as the presence of�2 tumors in the same animal. For a few ani-
mals, (n = 1 Osx-Cre;NT3 female and n = 3 FSP1-Cre;NT3 males) only the presence/absence of
tumors was recorded, but not location or number, so these were included only in tumor
latency data. No tumors were observed in Ctrl animals from either strain for ages up to 1 year.
Kaplan-Meier curves were used to calculate tumor latency.
Immunohistochemistry
Tumors were excised and fixed in 10% neutral buffered formalin. Paraffin-embedding and sec-
tioning to 4-5μm thickness was performed by the Musculoskeletal Research Center Histology
and Morphometry core at Washington University. Immunohistochemistry staining was com-
pleted by the Mouse Histology and Phenotyping Laboratory at Northwestern University.
Either a no primary negative (with goat primary) or IgG isotype negative (rabbit and rat pri-
maries) was used to confirm positive signal in stained sections. The TROMA-III hybridoma
product (CK19) developed by Kemler, R. was obtained from the Developmental Studies
Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of
Iowa, Department of Biology, Iowa City, IA 52242. Antibodies are listed in S2 Table. n = 3 for
each genotype, mixed male and female. Sex and location of tumors for images shown: H&E—
Osx-Cre;NT3 = female trunk; FSP1-Cre;NT3 = female trunk, GFP—Osx-Cre;NT3 = female per-
ineal; FSP1-Cre;NT3 = female perineal, RelB—Osx-Cre;NT3 = female perineal; FSP1-Cre;NT3
= female perineal, αSMA—Osx-Cre;NT3 = male facial, FSP1-Cre;NT3 = female perineal;
vimentin—Osx-Cre;NT3 = female perineal, FSP1-Cre;NT3 = female perineal; CK19—Osx-Cre;
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NT3 = female facial, FSP1-Cre;NT3 = female perineal; CD45—Osx-Cre;NT3 = female perineal,
FSP1-Cre;NT3 = female perineal; S100—Osx-Cre;NT3 = male facial, FSP1-Cre;NT3 = female
perineal. Whole slide images were acquired using standard brightfield settings on a NanoZoo-
mer 2.0 HT whole- slide scanner (Hamamatsu Photonics, Hamamatsu City, Shizuoka, Japan).
Negative control stains on additional tumor sections are provided in S1 Fig. Sections were
evaluated by Dr. Deborah J. Veis, a board-certified anatomic pathologist.
Genomic DNA recombination
Tumor, liver, and dorsal skin tissues were either stored in RNAlater (R0901, Millipore Sigma,
USA) at -20C or flash frozen in liquid nitrogen and stored at -80C˚. Sex and location of
tumors: mixed male and female, 2 facial and 1 perineal for Osx-Cre;NT3 or 2 perineal and 1
trunk for FSP1-Cre;NT3. gDNA was extracted from tissue samples as previously described
[26]. PCR cycling conditions using GoTaq polymerase (M7123, Promega, USA) are listed in
S3 Table. GelRed (41003, Biotium) was added at a concentration of 1:10,000 to agarose gels for
DNA visualization as well as a 1Kb Plus DNA Ladder (10787018, Invitrogen, USA) for band
size determination. Gel images were captured using a ChemiGenius 2 system using an ethid-
ium bromide filter with accompanying GeneSnap v7.12.02 software (Syngene, United
Kingdom).
RNA-Seq
Tumors were excised to remove any gross overlaying tissue, and either stored at -20C˚ in
RNAlater (R0901; Sigma, USA) or flash frozen in liquid nitrogen, and stored at -80C˚. Frozen
tumors were pulverized in liquid nitrogen followed by RNA extraction as previously described
[26]. Samples were screened by quantitative real-time PCR (qPCR) for blood- (Hba1, Hba2,
and Hbb) and monocyte-specific (CD68) markers to assess low peripheral blood content. Gene
expression was normalized to the levels of Gapdh, a housekeeping gene. qPCR primer
sequences are listed in S4 Table. A Nanodrop device (ND-2000; ThermoFisher, USA) and
other RNA quality assessments (Bioanalyzer 2100; Agilent Technologies, USA) were used to
determine RNA concentration and RNA integrity number (RIN score). Samples with suffi-
cient RNA yields as well as RIN scores and DV200 scores were prioritized for RNA-Seq analy-
sis as previously described [34, 35]. Final samples for analysis (n = 3 each genotype, all female,
Osx-Cre;NT3 = 3 trunk or FSP1-Cre;NT3 = 1 trunk and 2 perineal) had an average RIN score
of 7.7 for Osx-Cre;NT3 and 8.5 for FSP1-Cre;NT3.
RNA sequencing was performed at the Advanced Genomics Technology Center (Mayo
Clinic, Rochester, MN) using an Illumina HiSeq2500 sequencer as previously described [34,
35] with the following modifications. Raw reads were trimmed and aligned to the mouse
genome mm10 with Histat2 (Galaxy Version 2.1.0) using standard settings. Normalized reads
per gene (read count) and statistical analyses were performed using standard settings of fea-
tureCounts [36], a read summarization program which counts, quantifies, and assigns
sequencing reads for specific genomic features like mRNAs. Differential expression of genes
was calculated based on the above read counts using negative binomial generalized linear
models in DESeq2 [37]. Publicly available datasets were downloaded from NCBI’s Gene
Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/geo/) [38] and checked for quality
with FASTQC (Galaxy Version 0.72). Osx-Cre;NT3 and FSP1-Cre;NT3 tumors were grouped
together as NT3 tumors due to their high degree of similarity on principal component analysis.
Normalized reads per gene of NT3 tumors (group 1) were compared to a panel of benign tissue
datasets (group 2) including non-loaded cortical bone from Ctrl and Osx-Cre;NT3 mice
(GSE133212) [26], skeletal muscle (GSE83541) [39], white adipose tissue (GSE112999), mature
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cartilage (GSE110051), vein (GSE128870), dermal fibroblast (GSE60569) [40], blood
(GSE116630), and liver (GSE92364 [41], GSE93380 [42]). Individual sample files used for each
tissue type are listed in S5 Table. RNA-Seq data for the NT3 tumors have been deposited in
GEO under the accession number GSE158479. Differentially expressed genes were defined as
having fold changes (FC) >1.5 and a Benjamini-Hochberg adjusted p-value < 0.05 between
group 1 and group 2 (S6 Table).
Gene ontology (GO) analysis
The 1,314 DEGs listed in S6 Table were mapped to the Mus musculus reference genome
(22,265 reference IDs) using the PANTHER Overrepresentation Test (Released 20200407) for
GO biological process complete (Fisher’s exact test with FDR, p<0.05). Annotation version
and release date: GO Ontology database DOI: 10.5281/zenodo.3727280 Released 2020-03-23
(http://geneontology.org/). The final query for NT3 tumors included 1,022 unique IDs. Signifi-
cant biological processes (Fisher’s exact test FDR adjusted p-value < 1e-3) as well as unmapped
IDs (Riken clones, GM pseudogenes, and miRNAs) and IDs mapping to multiple genes are
listed in S7 Table.
Statistical analysis
Except for RNA-Seq analyses, statistics were computed using either GraphPad Prism v8 soft-
ware (GraphPad Software, Inc., USA) or SAS v9.4 (SAS institute Inc., USA). Normalized reads
per gene were log10-transformed and compared by one-way ANOVA followed by Dunnett’s
multiple comparisons test in Fig 5. For the continuous outcome of average number of tumors
per mouse, a two-way ANOVA was performed including strain, sex, and strain by sex interac-
tion followed by Sidak’s multiple comparisons test. A Fisher’s exact test was used to compare
differences in single vs multiple tumor incidence within and between strains and the false dis-
covery rate (FDR) adjustment was used to adjust p-values for the number of comparisons.
Kaplan-Meier curves for tumor latency were compared either within or between strains
using a standard log-rank (Mantel-Cox) test if the proportional hazard assumption was rea-
sonable. If the assumption was violated, an extended Cox proportional hazards model was
applied. For Osx-Cre;NT3 male and female mice, hazard ratios were calculated in two different
time intervals (t<125 days or t�125 days) by including two Heaviside functions (hv1 = 1�male
if t<125, hv1 = 0 if t�125; hv2 = 1�male if t�125; hv2 = 0 if t<125) with assumption that the
hazard ratios are constant in each time interval. Ctrl animals for each strain were considered
censored at the end of the follow-up period. Values of p<0.05 were considered significant, and
data are presented as mean ± SD. Sample sizes are indicated in the respective figure legends or
methods section.
Results
NT3 transgenic mice develop spontaneous soft tissue tumors in the
mesenchymal lineage
In the course of characterizing the bone phenotype of the Osx-Cre;NT3 mice [26], we observed
spontaneous soft tissue tumors. Based on their subcutaneous location and histological appear-
ance, we considered that a mesenchymal origin was likely, and therefore crossed the NT3
transgenic mice with a FSP1-Cre (S100a4) line [31], which predominantly shows expression in
the fibroblast population of multiple organs but has also been documented in the myeloid line-
age [31, 32, 43–45]. Beginning at 6 weeks of age, we monitored these mice for palpable tumor
masses 1–2 times per week.
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Both Osx-Cre;NT3 and FSP1-Cre;NT3 mice presented with spontaneous, superficial soft tis-
sue tumors with 100% penetrance (Fig 1A). Ctrl, Cre-negative littermates of either line, did not
develop tumors during a 1-year follow-up period. Tumors from both transgenic lines were
generally firm, beige, and nodular in appearance. Osx-Cre;NT3 mice had masses that were typ-
ically larger, more cystic, and predominantly (95% of males, 68% of females) found on or near
the face in the submandibular region. In addition to the face, Osx-Cre;NT3 animals also pre-
sented with tumors on the trunk (15% of males, 50% of females), perineal area (5% of males,
26% of females), and rarely on the limbs (1 female, 3%) (S2A Fig). FSP1-Cre;NT3 tumors often
became ulcerated and were most commonly found in the perineal region (78% of males, 100%
of females). Tumor locations for FSP1-Cre;NT3 animals also included the face (78% of males,
58% of females), localized mainly anterior on the snout, as well as the trunk (11% of males,
67% of females) and on the limbs (11% of males, 25% of females) (S2A Fig). Consistent with
the broader expression pattern of FSP1 in the mesenchymal lineage, we observed more tumors
on average (3.57 ± 1.83 vs 1.95 ± 2.02, ��p<0.0018) in FSP1-Cre;NT3 animals, in addition to
an earlier onset (79 vs 129 days, ����p<0.0001) versus their Osx-Cre;NT3 counterparts. Lastly,
radiographic imaging confirmed no overt bony tumors in either line that would be indicative
of an osteosarcoma (S2B Fig).
We next examined if there was a sex difference between the two mesenchymal Cre-driven
NT3 transgenic lines. There was no interaction between sex and strain for this between-group
comparison. However, the percentage of mice presenting with multiple tumors is significantly
higher with FSP1-Cre in both sexes (Fig 1B). The absolute number of tumors per mouse
revealed a similar upward trend in either sex in Osx-Cre;NT3 vs FSP1-Cre;NT3, but this was
only statistically significant in female mice (Fig 1C). The lack of statistical significance in male
animals in Fig 1C is likely due to the difference in sample sizes as there were nearly twice as
many animals in the Osx-Cre;NT3 vs the FSP1-Cre;NT3 cohort.
Analysis of the sex by time interaction indicated a time-varying hazard ratio between sexes
within the same strain only for Osx-Cre;NT3 mice (�p = 0.0173). A Cox proportional hazards
model in two different time intervals (t<125 days or t�125 days) was applied to test for a pos-
sible divergence in tumor latency by sex. In the first time interval (t<125 days), Osx-Cre;NT3
males had a longer tumor latency than females, but this difference was not statistically signifi-
cant. However, in the second time interval (t�125 days), Osx-Cre;NT3 males had a consider-
ably shorter tumor latency period than females (Fig 1A and 1D). A similar tumor latency was
observed between Osx-Cre;NT3 males with single vs multiple tumors (129 vs 126 days) (S2C
Fig). Osx-Cre;NT3 females that presented with multiple tumors had a markedly longer median
tumor latency period than females with only single tumors (161.5 days vs 112 days) (S2C Fig).
Notably, neither average number of tumors, multiple tumor incidence, nor tumor latency dif-
fered significantly between male and female FSP1-Cre;NT3 mice (Fig 1D, S2C Fig). Overall,
despite a mild statistical difference between male and female Osx-Cre;NT3 mice in tumor
latency, we concluded that the NT3 transgene was similarly oncogenic in both sexes of either
strain, and the primary differences between the strains were the shorter latency and higher
number of tumors with FSP1-Cre.
Spontaneous tumors derive from NT3 transgene expressing cells
To verify NT3 transgene expression in tumor tissue, we first performed PCR on gDNA from
whole tumors. Primers were designed to flank the loxP/Neo-STOP/loxP cassette [21]. In the
absence of Cre-mediated recombination, the intact allele results in a larger band, inefficiently
amplified in these PCR conditions (Fig 2A, NT3 Tg STOP). If the loxP/Neo-STOP/loxP cas-
sette is excised, a smaller band is present (Fig 2A, NT3 Tg GO). Tumors from both Osx-Cre;
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NT3 (Fig 2A, lanes 4–6) and FSP1-Cre;NT3 (Fig 2A, lanes 13–15) mice show robust recombi-
nation of the NT3 allele. Liver samples from these same mice served as a negative control for
the recombination event (Fig 2A, lanes 1–3; 10–12). A parallel PCR of the Crh, corticotropin
releasing hormone, locus was used as a positive control for gDNA extraction of whole tissue
preps (Fig 2A, bottom panel). Furthermore, as the location of these tumors was subcutaneous,
we also checked for presence of the recombination band in whole skin tissue to see if the
tumors were perhaps arising from Cre expression in dermal fibroblasts. The NT3 Tg GO prod-
uct was seen in skin from FSP1-Cre;NT3 mice (Fig 2A, lanes 16–18) but not in skin from Osx-
Fig 1. NT3 transgenic mice develop spontaneous soft tissue tumors. (A) Kaplan-Meier curves showing tumor
latency by sex in each strain. (B) Comparison between strains of males or females for the percentage of mice with� 2
tumors or (C) number of tumors per mouse. (D) Comparison by sex of the median tumor latency, average number of
tumors per mouse, and percentage of mice with� 2 tumors in Osx-Cre;NT3 and FSP1-Cre;NT3. Sample sizes are as
indicated. Results are presented as mean ± SD. Standard log-rank (Mantel-Cox) test or extended (time-varying) Cox
proportional hazards model for Kaplan-Meier curves. Two-way ANOVA followed by Sidak’s multiple comparisons
test for numbers of tumors per mouse or Fisher’s exact test with FDR adjustment for percentage of mice with� 2
tumors. �p<0.05, ��p<0.01.
https://doi.org/10.1371/journal.pone.0254426.g001
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Cre;NT3 (Fig 2A, lanes 7–9) or Ctrl animals (Fig 2A, lane 19), suggesting that FSP1-Cre drives
significant recombination in benign skin. FSP1-Cre is known to be expressed in dermal fibro-
blasts [31, 43], but was not found in keratinocytes [32]. Similarly, skin from Osx-Cre;Tdt
reporter mice did not show positive Tdt expression in keratinocytes (S3A and S3B Fig). Inter-
estingly, we did observe a rare population of Tdt+ cells in the dermis as well as in cultured der-
mal fibroblasts from Osx-Cre;Tdt mice (S3 Fig). These findings suggest that NT3 transgene
recombination occurs in dermal fibroblasts of both strains, with the greater extent in
FSP1-Cre;NT3 mice corresponding to a greater number and earlier onset of tumors.
H&E staining revealed a similar histologic pattern in both Osx-Cre;NT3 and FSP1-Cre;NT3
tumors. The tumors have a solid and sometimes nested growth pattern, usually with some
Fig 2. Tumors derive from NT3-transgene expressing cells. (A) gDNA PCR of whole tissue from liver, tumor, or skin in Osx-Cre;NT3, FSP1-Cre;NT3,
or Ctrl animals. Amplification across the loxP/Neo-STOP/loxP cassette in the intact allele or after Cre-mediated recombination. NT3 Tg = NT3
transgene. N = Cre-negative, Ctrl. Crh, corticotropin releasing hormone. (B) Representative H&E staining or (C) immunohistochemistry for GFP which
is expressed by the NT3 transgene as well as the Cre construct in Osx-Cre mice. (left images) 10x, scale bars = 250μM and (right images) 40x
magnification, scale bars = 50μM.
https://doi.org/10.1371/journal.pone.0254426.g002
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areas of elongated, spindled cell shapes. Tumor cells are enlarged, with pleomorphic nuclei
and frequent mitoses (Fig 2B). Some tumors have regional necrosis. Despite these aggressive
features, tumor borders were largely pushing rather than infiltrative. As both the NT3 trans-
gene and the Osx-Cre driver express a GFP tag, we used an antibody to GFP to immunostain
the tumors. The majority of tumor cells (75–100%) are GFP-positive in both Osx-Cre;NT3 and
FSP1-Cre;NT3 tumor samples (Fig 2C). The immunostained sections also highlight nests of
tumor cells at the dermal-epidermal junction in many FSP1-Cre;NT3 tumors (Fig 2C, bottom
right).
NT3 tumors share markers of soft tissue sarcomas
We next sought to determine the cellular origin of these spontaneous tumors using immuno-
histochemistry (Fig 3). Use of either the Osx-Cre or FSP1-Cre drivers targets NT3 transgene
expression to the mesenchymal lineage. However, evidence for NF-κB, and particularly alter-
native NF-κB, in the pathogenesis of sarcomas is very limited and largely associative [46]. Nev-
ertheless, we proceeded to investigate two well-known mesenchymal lineage markers, alpha-
smooth muscle actin (αSMA) and vimentin (Vim), for which anti-mouse antibodies are avail-
able. Both Osx-Cre;NT3 and FSP1-Cre;NT3 tumors (n = 3 of each) exhibit moderate to strong
αSMA staining in at least 60% of the tumor cells. Strong expression of Vim was seen in most
(70–80%) tumor cells from Osx-Cre;NT3 animals, but Vim staining was restricted to the
periphery in FSP1-Cre;NT3 tumors, where 20–50% of cells were weakly to moderately positive.
Furthermore, staining of the epithelial marker, cytokeratin 19 (CK19), revealed a dichotomous
expression pattern in these tumors with areas of positive as well as negative staining within the
tumor mass. Interestingly, the CK19+ cells appeared morphologically distinct as large, spin-
dle-shaped cells compared to the smaller, rounder tumor cells.
Both the Osx-Cre and FSP1-Cre drivers have been previously shown to have off-target
effects outside of the mesenchymal lineage, most notably in cells of hematopoietic origin [32,
33, 44, 45, 47, 48]. To this end, we assayed CD45 expression. While tumor samples from both
mesenchymal Cre-drivers showed positive CD45 staining, this appeared to be restricted to the
inflammatory infiltrate. FSP1-Cre;NT3 tumor samples exhibited a higher degree of this CD45
infiltrate, most likely owing their propensity to be superficially ulcerated at presentation.
As melanoma is almost always part of the diagnostic workup for a poorly differentiated sub-
cutaneous tumor in patients, we checked for S100 expression [49]. Remarkably, both
Fig 3. NT3 tumors have features of soft tissue sarcomas. Immunohistochemical staining of representative Osx-Cre;
NT3 (top) and FSP1-Cre;NT3 (bottom) tumors for hematoxylin and eosin (H&E), alpha-smooth muscle actin (αSMA),
vimentin (Vim), Cytokeratin 19 (CK19), CD45, and S100 protein. Scale bars = 500μM. Insets are taken from boxed
regions, with scale bars = 50μM.
https://doi.org/10.1371/journal.pone.0254426.g003
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FSP1-Cre;NT3 and Osx-Cre;NT3 tumors were negative for S100 staining, except for a few indi-
vidual cells that are likely skin macrophages that have taken up melanosomes from benign
melanocytes. In sum, the totality of the above morphological and immunohistochemistry evi-
dence suggests that these spontaneous tumors represent a poorly differentiated, aggressive
sarcoma.
NF-κB /NF-κB -related biological processes are enriched in NT3 tumors
To gain insight into both the possible cellular origin and pathogenesis of these spontaneous
tumors, we performed RNA-Seq analysis of tumors from both Osx-Cre;NT3 and FSP1-Cre;
NT3 mice. We performed principal component analysis (PCA) of tumors and a panel of
benign tissues using publicly available datasets from NCBI’s Gene Expression Omnibus
(GEO) [26, 39–42] (S5 Table), including cortical bone samples from Osx-Cre;NT3 and litter-
mate Ctrl. We also included two tissues or cell types of non-mesenchymal origin (e.g. blood
and liver) as biological outgroups for PCA and hierarchical clustering. As expected, tumors
from both lines segregated away from both blood and liver samples (Fig 4A). Notably, the Osx-
Cre;NT3 tumors clustered more closely with the FSP1-Cre;NT3 tumors than to cortical bone
from Osx-Cre;NT3 mice [26]. Both Osx-Cre;NT3 and FSP1-Cre;NT3 tumors did not signifi-
cantly overlap with any other mesenchymal tissue assayed (muscle, vein, fat, cortical bone, der-
mal fibroblast) except for mature cartilage. Anatomically, these tumors were not found near
any cartilaginous sites, and histologically they did not show indications of cartilage differentia-
tion such as lacunar morphology or matrix production. Furthermore, expression of selected
cartilage and muscle marker genes was low compared to their respective benign tissues (S4
Fig). Based on this analysis, we concluded that the Osx-Cre;NT3 and FSP1-Cre;NT3 tumor
expression profiles most closely match one another, suggesting a distinct, but as yet unclear,
developmental origin.
Due to their high degree of similarity, we grouped together Osx-Cre;NT3 and FSP1-Cre;
NT3 tumors (NT3 tumors) and compared them to all remaining tissues shown in Fig 4A to
generate a list of differentially expressed genes (DEGs). We further filtered the DEG list to
only those genes with a fold-change (FC)>1.5 (S6 Table) as NF-κB chiefly functions as an acti-
vating transcriptional program. Moreover, the vast majority of DEGs in our previous study
comparing Ctrl bone to Osx-Cre;NT3 bone showed that differences skewed strongly towards
increased, and not decreased, target gene expression as a result of the NT3 transgene [26].
Inspection of the DEG list did not yield any evidence of a single oncogenic driver and/or
tumor suppressor. Importantly, we did not observe abnormal expression levels of oncogenes
known to lead to NF-κB activation including p53, KRAS, EGFR, or PI3K [3]. However, this
lack of evidence could be due to the absence of a true matched reference for our NT3 tumors
since their etiology remains unknown.
As individual genes are rarely biologically informative in isolation, we performed pathway
analysis. Gene ontology (GO) analysis for biological process (BP) of the 1,314 DEG genes from
above (S6 Table) revealed 509 GO BP terms, 170 of which were highly significant (FDR
adjusted p-value <1e-3; S7 Table). To distill out the key pathways driving spontaneous tumor
formation in Osx-Cre;NT3 and FSP1-Cre;NT3 mice, we further refined our search to those pro-
cesses with a fold-enrichment� 3 relative to the expected incidence in the mouse genome (Fig
4B). The most overrepresented program, with a 6.22 fold-enrichment score, was the GO term
for inflammatory response to antigenic stimulus (GO:000243) while the GO term for regula-
tion of IKK/NF-κB signaling (GO:0043122) displayed a 3-fold enrichment. Of the 22 total GO
BP shown in Fig 4B, 73% (16/22 –black bars) are known NF-κB/NF-κB related terms, predom-
inated by inflammation and immune processes. Other NF-κB related GO terms of interest
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include intrinsic apoptotic signaling pathway in response to DNA damage (GO:0008630) and
both positive regulation of lymphocyte proliferation (GO:0050671) and positive regulation of
mononuclear cell proliferation (GO:0032946), as these may indicate possible tumor cell prolif-
eration. The remaining 27% GO BP (6/22 –white bars) represent skin development, particu-
larly of the epidermis, which is likely contamination of overlaying skin incidental from gross
tumor excision.
We next performed a gene set enrichment analysis (GSEA) focused on NF-κB related gene
sets to determine if NT3 tumors and NT3 bone [26] would co-segregate, reflecting common
transgene targets. However, with the large number of genes represented (~500 genes,
Fig 4. NT3 tumors cluster together and show upregulation of NF-κB biological processes. (A) Principal component analysis of Osx-Cre;NT3 tumors and
FSP1-Cre;NT3 tumors vs Ctrl bone and Osx-Cre;NT3 bone (marked with an �) as well as other benign tissues—muscle, fat, vein, dermal fibroblast, mature
cartilage, blood, liver. (B) Gene ontology (GO) analysis of NT3 tumors vs the same panel of tissues in (A) showing the top biological processes (BP) with fold-
enrichment� 3 and a Fisher’s exact FDR adjusted p-value< 1e-3. black bars = NF-κB /NF-κB related processes; white bars = skin/epithelial processes.
https://doi.org/10.1371/journal.pone.0254426.g004
PLOS ONE Constitutive activation of NIK in the mesenchymal lineage drives spontaneous soft tissue sarcoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0254426 July 22, 2021 12 / 22
S8 Table), the tissue signature predominated, and all bones clustered with each other and away
from the tumors (S5 Fig). To more specifically focus on NT3 transgene targets, we turned to
our previous comparison of gene expression in age/sex/tissue matched Osx-Cre;NT3 and Ctrl
bone. PCA of the top 20 DEGs and 3 NF-κB pathway genes that were upregulated in Osx-Cre;
NT3 vs Ctrl bones was performed, including all of the samples used in Fig 4A. All of the non-
transgenic tissues including bone clustered together, and although the NT3-expressing tumors
and NT3 bone were distinct from each other, they segregated away from this large cluster (Fig
5A). To further demonstrate NF-κB activation, we compared expression of the 3 NF-κB genes
(Fig 5B), as well as several DEGs (Fig 5C), each with 2 or more κB response elements. Strik-
ingly, the vast majority of these normal tissues had much lower levels of expression of all of
these NF-κB targets, despite the varied tissues represented, and there were only rare cases in
which individual tissues showed expression comparable to the NT3 tumors.
With this strong evidence of NF-κB upregulation in tumors, we turned to immunostaining
to verify that the tumor cells themselves, rather than tumor stroma, show pathway activation.
RelB is the principal NF-κB subunit downstream of NIK responsible for modulation of gene
transcription. Strikingly, both Osx-Cre;NT3 and FSP1-Cre;NT3 mice show robust nuclear
staining of RelB in all tumors (Fig 6A and 6B). Furthermore, there is a clear distinction
between the uniformly RelB-positive tumor cells versus RelB-negative stromal cells. The
majority of cells in adjacent benign tissues also lack nuclear RelB. Based on these gene expres-
sion and immunohistochemistry data, together with the presence of the Cre-mediated recom-
bination product, in two distinct mouse lines, we concluded that NT3-initiated tumor
formation is indeed driven by NF-κB activation.
Discussion
Although the initial discovery of NF-κB arose from observations that the v-rel viral oncogene
and translocations of c-rel can be oncogenic in lymphocytes, few mutations in genes of the
NF-κB pathway have clear oncogenic effects [50]. In fact, the NT3 transgene used here was
first generated after multiple genetic aberrations in the alternative NF-κB pathway were identi-
fied in B cell malignancies. However, removal of the negative regulatory TRAF3-binding
domain of NIK in this transgene was insufficient to cause oncogenesis in the B cell lineage
[21–23]. Other studies have expressed the NT3 transgene in hematopoietic stem cells, T cells,
myeloid cells, intestine, pancreatic islets, and hepatocytes, without reports of malignant trans-
formation [51–56]. NF-κB expression is found both within the epidermal and dermal layers of
the skin with expression in the dermis restricted to dermal fibroblasts [57]. Intact NF-κB sig-
naling, particularly upstream kinase activation, is essential to maintain epidermal homeostasis
and to prevent squamous cell carcinoma [14]. Therefore, the presentation of subcutaneous
tumors in Osx-Cre;NT3 mice was unexpected. Our initial motivation in generating these con-
ditional transgenic mice was to understand the role of alternative NF-κB in osteogenic cells,
where Osx is highly expressed, but we never observed any bone tumors. Based on the location
and histologic appearance, we hypothesized that the cell of origin was likely mesenchymal and
in the dermis or subcutaneous soft tissues, and we were able to replicate the tumor phenotype
with a Cre driver with that expression pattern, FSP1-Cre. Together, these two mouse lines dis-
playing spontaneous tumorigenesis indicate that the loss of TRAF3 binding in NIK can be
oncogenic in certain cellular contexts.
We used immunohistochemistry to attempt to classify NT3 tumors by cell of origin. Both
Osx-Cre and FSP1-Cre driven NT3 tumors expressed the marker αSMA in most malignant
cells, while vimentin staining was present, although more variable, in the latter colony. It is not
clear why vimentin was less consistently expressed than αSMA. Nevertheless, αSMA and GFP
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Fig 5. Tumors show strong expression of NF-κB target genes. (A) Principal component analysis of Osx-Cre;NT3
tumors and FSP1-Cre;NT3 tumors (marked with �), Ctrl and Osx-Cre;NT3 bone, and other normal tissues utilizing the
23 genes listed. Expression of (B) NF-κB genes (Nfkbia, Nfkb2, and Relb) and (C) 9 additional NT3 transgene targets
previously identified as top DEGs in NT3 bone vs Ctrl bone, each with 2 or more κB response elements. Log10(reads
per gene) is shown from normalized RNA-Seq data. One-way ANOVA, followed by Dunnett’s multiple comparisons
test; �, p<0.05, ��p<0.01; ���, p<0.001; ����, p<0.0001.
https://doi.org/10.1371/journal.pone.0254426.g005
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showed a very high degree of concordance. A mesenchymal origin is also aligned with that
expected from the overlap in pattern of these Cre drivers. Thus, the totality of the evidence
points towards a mesenchymal origin without differentiation towards a specific lineage. The
classification of poorly differentiated sarcomas is notoriously difficult, with a paucity of diag-
nostic antibodies for mesenchymal populations, compounded here by limited cross-reactivity
of antibodies to test tumors of murine rather than human origin. The presence of a significant
population of CK19+ cells in both tumor types, in populations of large and pleomorphic cells
indicative of tumor rather than host cells, is somewhat confounding. CK19 expression has
been described mainly in thyroid, gastroenteropancreatic and hepatobiliary tumors [58, 59].
Because of the unique combination of location, overall histology, and expression patterns of
the two Cre drivers, we consider an epithelial origin unlikely. The calcium binding protein
S100, a marker that is highly expressed in melanomas, was completely absent in our tumors,
and this result argues against a melanocytic derivation. Although expression of both Osx-Cre
and FSP1-Cre alleles has been observed in CD45+ cells [32, 33, 44, 45, 48], the absence of
CD45 in the tumor cells indicates that a hematopoietic origin is unlikely. In further support of
this conclusion, expression of this NT3 transgene in various hematopoietic cells did not result
in malignancy [51–53].
We next attempted further classification of NT3 tumors using RNA-Seq data and PCA,
which suggested that the tumors are distantly related to tissues with cartilage expression signa-
tures. However, histologic features are not consistent with a chondrogenic origin, which also
seems unlikely in dermal or subcutaneous mesenchyme, and cartilage marker genes are poorly
expressed. The NT3 transgene is expressed in the skin of both FSP1-Cre;NT3 and Osx-Cre;NT3
animals, but PCA analysis did not indicate shared features with normal dermal fibroblasts. As
bulk RNA-Seq analysis of NT3 tumors is unlikely to uncover significant similarity to a distinct
subpopulation of dermal fibroblasts, this does not rule out a dermal origin for tumorigenesis.
Undoubtedly, our RNA expression analysis is limited by the datasets used for comparison.
Without clear hypotheses to indicate other tissues or cells to include, further comparisons are
outside the scope of this study. Such work might include filtering the data to reduce the
Fig 6. The NT3 transgene activates alternative NF-κB in tumor cells. Immunostaining for RelB in (A) Osx-Cre;NT3 or (B) FSP1-Cre;
NT3 tumors. RelB is uniformly nuclear in malignant cells, indicating robust activation of the alternative NF-κB pathway. Few cells in
adjacent benign tissues show significant staining for RelB. SG, salivary gland; LN, lymph node; SkM, skeletal muscle; Es, esophagus.
Scale bars = 100μM. n = 3 each genotype.
https://doi.org/10.1371/journal.pone.0254426.g006
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keratinocyte signature, since the tumors do not appear to have an epidermal origin, as well as
comparisons to a panel of murine mesenchymal and perhaps epithelial tumors. Finally, one
intriguing possibility is a follicular dendritic cell sarcoma, which can arise from ubiquitous
perivascular cells, and in humans can show aberrant NF-κB regulation and high expression of
CXCL13, an alternative NF-κB driven gene [60].
Based on early studies employing overexpression, NIK was originally named for its ability
to activate classical NF-κB signaling [61]. Although it was later shown to be dispensable for
this function, various studies employing the constitutively activated NIK allele used here have
shown induction of both classical and alternative NF-κB signaling [1]. RNA-Seq analysis of
NT3-driven tumors demonstrates activation of κB-responsive genes including RelB, but it is
not clear if tumorigenesis requires classical and/or alternative signaling. Therefore, additional
studies utilizing mice deficient in downstream components specific to each pathway would be
required to demonstrate whether one or both pathways are necessary for the observed
tumorigenesis.
The variable time to emergence of the NT3 tumors, as well as a relatively small average
number of tumors per mouse, suggests that a second genetic hit is likely needed in addition to
NIK activation for oncogenic transformation. Previous studies have shown that Bcl6 [22] and
Notch [23] collaborate with the NT3 transgene to generate tumors. Yet, pathway analysis of
RNA-Seq data from NT3 tumors compared to several benign tissues failed to identify other
clear oncogenic signals, including pathways such as p53 that have previously been linked to
sarcomagenesis [46, 62]. Our study remains limited by the lack of a corresponding benign
comparator to the cell of origin. Furthermore, chromosomal translocations are also a common
feature of sarcomas, and we have not queried for this form of genomic change in the NT3
tumors.
Although we wish to emphasize that the NT3 transgene drove tumors in both sexes, with
two different Cre drivers, we did observe some differences between the groups. With regard to
the Cre driver, tumors in FSP1-Cre;NT3 mice of both sexes appeared with shorter latency and
in greater numbers. This is most likely a direct effect of constitutive expression of the FSP1-Cre
allele in dermal fibroblasts. Cre expression in Osx-Cre;NT3 mice, on the other hand, was
induced postnatally in our studies, and detected only in a rare population of dermal fibroblasts.
Despite subtle variations by sex in tumor latency in the Osx-Cre;NT3 mice, none were present
in the FSP1-Cre;NT3 line. Many Osx-Cre;NT3 males in our colony were utilized for other
experiments prior to the appearance of tumors [26] and, therefore, the number of animals
between sexes in this strain was not balanced. We also had fewer FSP1-Cre;NT3 mice of both
sexes, as these were generated later. The discrepancy in group size may have influenced the
outcome of the sex-by-strain statistical analysis. Nevertheless, despite the fact that we previ-
ously observed sex differences in bone phenotype with modulation of the alternative NF-κB
pathway [63], there appears to be little to no biologically significant effect of sex on tumorigen-
esis suggesting that NT3 tumors form independent of male or female sex steroids.
In summary, we describe here a new, 100% penetrant, spontaneous soft tissue tumor model
in mice expressing an activated form of NIK, the apex kinase in the alternative NF-κB path-
way. Tumors arose using two distinct Cre-driver strains with overlapping mesenchymal line-
age expression, supporting our conclusion that this mutant NIK allele has oncogenic potential.
While NF-κB activation is a feature of many types of hematopoietic and epithelial tumors, it
has not previously been intimately associated with mesenchymal tumors. Our observation that
this particular NIK allele seems to have oncogenic potential only in the latter cell ontogeny
suggests that there is much we do not yet understand about the role of NF-κB in cancer, specif-
ically in the sarcoma setting.
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Supporting information
S1 Fig. IHC negative control staining. (A) No primary antibody stain for anti-goat GFP-bio-
tin antibody. (B) Rat IgG background staining for CK19 antibody. (C) Rabbit IgG background
staining for αSMA, vimentin, CD45, and S100 protein antibodies. All negative control stains
were performed on Osx-Cre;NT3-tumor sections. Top row for each panel is 10x and the bot-
tom row for each panel is 40x magnification. Scale bars = 100μM.
(TIF)
S2 Fig. Additional tumor information for Osx-Cre;NT3 and FSP1-Cre;NT3 mice. (A) Num-
ber of Osx-Cre;NT3 and FSP1-Cre;NT3 mice presenting with a tumor mass at different ana-
tomical locations. In the case of multiple tumors within the same animal, the animal was
counted once in each category for 1 or more masses at a given location. (B) Representative
radiographic images revealing no overt osseous tumors in either strain. scale bar = 3mm. (C)
Median tumor latency for Osx-Cre;NT3 and FSP1-Cre;NT3 animals presenting with single or
multiple (�2) tumors. Samples sizes are as indicated in each panel. Standard log-rank (Man-
tel-Cox) test: ����p<0.0001.
(TIF)
S3 Fig. Rare population of Tdt+ dermal fibroblasts in Osx-Cre;Tdt mice. (A) Direct fluores-
cence of Tdt with DAPI counterstain in frozen skin sections from Ctrl or (B) Osx-Cre;Tdt
mice. Representative 20x images shown with white arrows denoting Tdt+ cells. Scale
bars = 20μm. (A’-B’) Higher magnification of boxed areas in A-B. Scale bars = 5μm. n = 2 each
genotype. (C) Flow cytometry analysis for Tdt in cultured skin fibroblasts from Ctrl or Osx-
Cre;Tdt mice. n = 3 each genotype. Unpaired one-tailed t-test with Welch’s correction:
�p<0.05.
(TIF)
S4 Fig. Low expression of cartilage and muscle markers in Osx-Cre;NT3 and FSP1-Cre;NT3
tumors. (A) Expression of cartilage markers or (B) muscle markers in NT3 tumors versus the
respective tissue. Log10(reads per gene) is shown from normalized RNA-Seq data. Mann Whit-
ney U test; �, p<0.05, ��p<0.01.
(JPG)
S5 Fig. Tissue signature dominates over NT3 transgene signature in broad NF-kB gene list.
Principal component analysis of Osx-Cre;NT3 tumors, FSP1-Cre;NT3 tumors, Osx-Cre;NT3
bone, and Ctrl bone using genes from a gene set enrichment analysis (GSEA) of top NF-κB
related gene sets listed in S8 Table.
(PNG)
S6 Fig. Raw gel image for Fig 2.
(TIF)
S1 Table. Genotyping conditions.
(XLSX)
S2 Table. List of antibodies.
(XLSX)
S3 Table. Genomic DNA recombination conditions.
(XLSX)
S4 Table. q-RT-PCR primers for peripheral blood and monocyte markers.
(XLSX)
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S5 Table. GEO datasets for Osx-Cre;NT3 and FSP1-Cre;NT3 tumors and benign tissues.
(XLSX)
S6 Table. Mean normalized counts for DEG list between NT3 tumors and benign tissues.
(XLSX)
S7 Table. GO analysis for top DEGs.
(XLSX)
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